 In patients with DLBCL with non-GCB, however, negative expression of CD99 resulted in better 2-year EFS and 2-year OS.In patients with non-small cell lung cancer (NSCLC), higher CD99 expression in the stroma results in better prognosis.There is evidence that through suppressing β1 integrin affinity, CD99 inhibits cell-extracellular matrix adhesion.